CereVasc closes oversubscribed $85M Series C to advance eShunt for hydrocephalus
What's the deal? CereVasc, a clinical-stage medical device company based in Massachusetts, has closed an oversubscribed $85M Series C financing round. The company is developing the eShunt System, a minimally invasive treatment for Normal Pressure Hydrocephalus (NPH) — a neurological condition where current surgical options remain inadequate.
Piper Sandler Merchant Banking led the round, with new investors Johnson & Johnson Innovation (JJDC) and MedtronicDealroom has a profile for this one. Try Dealroom → joining existing backers Bain Capital Life SciencesDealroom has a profile for this one. Try Dealroom → and Perceptive Xontogeny Venture FundsDealroom has a profile for this one. Try Dealroom →.
The funds will support completion of CereVasc's STRIDE pivotal trial, a multi-centre randomised controlled study comparing the eShunt System against the standard ventriculo-peritoneal (VP) shunt. Proceeds will also go toward a future Premarket Approval (PMA) submission to the FDA and preparations for US commercialisation.
Why now? CereVasc's STRIDE trial is already underway, and the company needs capital to see it through to completion. The round also comes as it scales operations ahead of a potential commercial launch — a stage that demands significant investment in regulatory work, manufacturing, and go-to-market infrastructure.
The company bolstered its board alongside the raise, adding Kevin Conroy as lead independent director, Christopher Geyen as audit committee chair, and Tom Schnettler of Piper Sandler representing Series C investors.
What could go wrong? CereVasc is still pre-approval. The STRIDE trial must demonstrate that the eShunt System is both safe and effective versus the VP shunt — a decades-old standard of care — before the FDA will consider a PMA submission. Clinical setbacks or regulatory delays could push commercialisation timelines significantly.
NPH is also notoriously underdiagnosed, often mistaken for other age-related conditions like dementia. Even with an approved product, CereVasc would need to build physician awareness and referral pathways to generate meaningful adoption.
The signal: CereVasc's oversubscribed Series C — backed by corporate investors Medtronic and Johnson & Johnson Innovation alongside specialist life sciences funds Bain Capital Life Sciences and Perceptive Xontogeny — illustrates how minimally invasive neurology devices are attracting both financial and strategic capital simultaneously. The dual presence of two of the world's largest medtech corporates on the cap table at the late growth stage points to genuine commercial validation, not just venture optimism, as the company moves toward a potential FDA approval and US launch.
Read more: PR Newswire (via Chase IDC)
